| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BCP.2011.02.005 |
| P698 | PubMed publication ID | 21333634 |
| P50 | author | Laura K K Pacey | Q81154424 |
| P2093 | author name string | David R Hampson | |
| Daniel C Adusei | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autism | Q38404 |
| fragile X syndrome | Q221472 | ||
| autism spectrum disorder | Q1436063 | ||
| P304 | page(s) | 1078-1086 | |
| P577 | publication date | 2011-02-17 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome | |
| P478 | volume | 81 |
| Q38030914 | Astrocytes and developmental plasticity in fragile X. |
| Q47882426 | Improved efficiency of asymmetric hydrolysis of 3-substituted glutaric acid diamides with an engineered amidase |
| Q50476272 | Microbial asymmetric hydrolysis of 3-substituted glutaric acid diamides. |
| Q49775943 | Neurogenetics: Five new things |
| Q35009426 | Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders |
| Q37972081 | Pathways to drug development for autism spectrum disorders |
| Q37065273 | Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [¹H]MRS study. |
| Q35188148 | Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome |
| Q37976331 | The medical care of children with autism |
| Q27010675 | The pathophysiology of fragile X (and what it teaches us about synapses) |
| Q27025923 | The unstable repeats--three evolving faces of neurological disease |
| Q36712349 | Translational approaches to the biology of Autism: false dawn or a new era? |
| Q38046662 | mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders |
Search more.